AnaptysBio 2025 Q1 Earnings Narrower Losses as Net Income Improves 10.5%

AnaptysBio (ANAB) reported its fiscal 2025 Q1 earnings on May 05th, 2025. AnaptysBio's earnings results for Q1 2025 showed a narrower net loss than anticipated, with a reported loss of $1.28 per share compared to the Zacks Consensus Estimate of a loss of $1.30 per share. The company did not adjust its guidance, maintaining expectations of presenting updated clinical data in early June and releasing ulcerative colitis data in Q4 2025. AnaptysBio remains confident in its financial position with a cash runway extending through year-end 2027.

Revenue

AnaptysBio experienced a substantial increase in total revenue for Q1 2025, reaching $27.77 million, marking a 286.8% rise from $7.18 million in Q1 2024. The collaboration revenue was the sole contributor, accounting for the entire $27.77 million revenue figure. This significant growth reflects the effectiveness of the company's strategic partnerships and agreements.

Earnings/Net Income

AnaptysBio narrowed its Q1 2025 losses to $1.28 per share, showing a 22% improvement from the previous year's loss of $1.64 per share. The company reduced its net loss by 10.5%, with a reported loss of $39.33 million compared to the $43.94 million net loss in Q1 2024. Despite the ongoing financial challenges, the improvement in EPS suggests a positive outlook for AnaptysBio.

Price Action

The stock price of AnaptysBio edged up 0.18% during the latest trading day, dipped 2.81% over the most recent trading week, and jumped 9.28% month-to-date.

Post-Earnings Price Action Review

Investing in AnaptysBio shares post-earnings and holding for 30 days has historically resulted in poor performance over the past five years. This strategy yielded a return of -79.01%, significantly underperforming the benchmark return of 82.65%, leading to an excess return of -161.66%. The compound annual growth rate (CAGR) stood at -27.06%, indicating substantial losses. This approach also faced a high maximum drawdown of -84.60%, coupled with a Sharpe ratio of -0.54, highlighting significant risk and negative returns associated with this investment strategy.

CEO Commentary

“Rosnilimab delivered impressive three-month Phase 2b efficacy, safety and tolerability data in rheumatoid arthritis (RA), with data through six months surpassing those of competitor all-active, head-to-head trials,” said Daniel Faga, President and Chief Executive Officer of AnaptysBio. He emphasized the company’s strong pipeline, noting, “With ANB033 and ANB101 progressing through Phase 1 trials, our autoimmune portfolio promises multiple catalysts over the next couple of years.” Faga expressed optimism about the company's financial position, stating, “We remain well-capitalized as we execute on our broad development plan for all three programs.”

Guidance

AnaptysBio anticipates presenting updated clinical and translational data for rosnilimab in the first week of June and expects to release initial Phase 2 ulcerative colitis data in Q4 2025. The company reiterates its cash runway extending through year-end 2027 and expects to receive a $75 million commercial sales milestone payment from GSK in either 2025 or 2026 once Jemperli achieves $1 billion in worldwide net sales within a calendar year.

Additional News

AnaptysBio has been actively engaging in strategic initiatives beyond its earnings results. In March 2025, the company announced a $75 million stock repurchase program, aimed at enhancing shareholder value. Additionally, AnaptysBio entered into an exclusive $15 million global out-license agreement with Vanda Pharmaceuticals for the development and commercialization of imsidolimab, its IL-36R antagonist. This agreement includes potential regulatory approvals and sales milestone payments up to $35 million, along with a 10% royalty on global net sales. Furthermore, AnaptysBio's collaboration with GSK continues to benefit from the strong performance of Jemperli, which reported $220 million in Q1 2025 sales, showcasing over 15% quarter-over-quarter growth.